Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

Basit Öğe Kaydı
dc.authoridtunbekici, salih/0000-0001-8804-7636
dc.authoridYuksel, Haydar Cagatay/0000-0001-8857-2983
dc.authoridBiter, Sedat/0000-0002-1053-0668
dc.authoridCoskun, Alper/0000-0003-2444-6587
dc.authoridmajidova, nargiz/0000-0002-2575-5819
dc.authoridKOLKIRAN, NAGIHAN/0000-0001-9344-7212
dc.authoridSeyyar, Mustafa/0000-0002-4841-7994
dc.contributor.authorTunbekici, Salih
dc.contributor.authorYuksel, Haydar cagatay
dc.contributor.authorAcar, Caner
dc.contributor.authorSahin, Goekhan
dc.contributor.authorOrman, Seval
dc.contributor.authorMajidova, Nargiz
dc.contributor.authorCoskun, Alper
dc.date.accessioned2025-02-22T14:08:41Z
dc.date.available2025-02-22T14:08:41Z
dc.date.issued2025
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of <= 2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18-67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23-2.75) and a median overall survival of 4.1 months (95% CI: 3.52-4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0-1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.en_US
dc.identifier.doi10.3390/cancers17010046
dc.identifier.issn2072-6694
dc.identifier.issue1en_US
dc.identifier.pmid39796675en_US
dc.identifier.scopus2-s2.0-85214451268en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/cancers17010046
dc.identifier.urihttps://hdl.handle.net/11468/29564
dc.identifier.volume17en_US
dc.identifier.wosWOS:001393408200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectregorafeniben_US
dc.subjectrecurrent glioblastomaen_US
dc.subjectsafetyen_US
dc.subjectefficacyen_US
dc.subjecttargeted therapyen_US
dc.subjectreal-worlden_US
dc.titleRegorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu